Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVTR 101

Next Previous
Drug Profile

AVTR 101

Alternative Names: AVTR-101

Latest Information Update: 24 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aventi Biotechnology
  • Class
  • Mechanism of Action MYMK protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Sarcopenia

Most Recent Events

  • 11 Feb 2025 Aventi Biotechnology plans to launch AVTR 101 for Sarcopenia by 2027 (Aventi Biotechnology website, February 2025)
  • 16 Jan 2025 Aventi Biotechnology terminates a phase-II trial in Sarcopenia (In the elderly) in South Korea (PO), due to delays in subject enrollment and the expiration of the test drug, concluding that halting the trial was necessary to minimize enrollment delays and enhance the efficiency of the clinical program (NCT06788236)
  • 14 Jan 2025 PharmAbcine and Aventi Biotechnology agree to co-develop AVTR101 for the treatment of sarcopenia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top